...
16/9/13 1pm | PUW3 | Joe | Diagnostics for bivariate regression models |
23/9/13 1pm | PUW3 | No meeting | Julie Seminar on Tues 24/9. |
30/9/13 1pm | PUW2 | Jan-Stefan Van der Walt | Nonlinear mixed effects model for saliva cortisol and cortisone in patients with Addisons disease and healthy volunteers. |
1/10/13 1pm EXTRA MEETING | PUW4 | Stefanie Hennig | Changes in between subject variability with covariate models in pharmacometrics |
7/10/13 1pm | PUW2 |
|
|
14/10/13 1pm | PUW3 | Tafi | TBA |
21/10/13 1pm | PUW2 | Julie | Modelling of tenofovir and emtricitabine PK in the ANRS 134-COPHAR 3 trial (work in progress) |
28/10/13 1pm | PUW3 | Joanna | CD4 recovery in the CHER study |
4/11/13 1pm | PUW2 | Eva | Upgrade talk practice |
11/11/13 1pm | PUW3 | Flora Musuamba | Use of modelling and simulation tools to improve decision-making in drug development and clinical practice |
18/11/13 1pm | PUW2 | Joe | Decision theory and antimicrobials |
25/11/13 1pm | PUW3 | Andreas | Pain PKPD |
2/12/13 1pm | TWC F | No meeting |
|
9/12/13 1pm | PUW3 | Pieter de Cock | Paediatric antimicrobial PKPD in ICU |
16/12/13 1pm | PUW3 | Rollo | Modelling TCR repertoire (not with NLME!) |
20/1/14 | PUW3 | Jessica Soto | Modelling taste studies |
27/1/14 | PUW1 | Joanna | Practice for South Africa |
3/2/14 | PUW3 | Liana | PK of tyrosine kinase inhibitors in PKD animal model |
10/2/14 | PUW4 | Eva | Neogent predictions |
17/2/14 | PUW3 | Deji | Hepatitis and HIV co-infection modelling |
24/2/14 | PUW1 |
|
|
3/3/14 | PUW2 | Rollo | Upgrade practice |
10/3/14 | PUW1 | Joe | Clonidine PKPD for sedation in PICU |
17/3/14 | PUW3 | Andreas | Clinical protocol development for GAbapentine in Paediatric pain Project : Optimization of the trial design characteristics based on (E)D optimality using popED. |
24/3/14 | PUW3 | Julie | MRC Biostats talk on new methods for genetic covariates in PKPD modelling. |
31/3/14 | PUW1 | Flora | Clinical protocol development for GAbapentine in Paediatric Pain Project : Dose rationale and dosing schedule for characterisation efficacy in chronic pain |
7/4/14 | PUW3 | Morris | Development and dose rationale for fixed dose combinations for the treatment of tuberculosis |